Biotech · Hong Kong, MA · Founded 2014 · Publicly Held
InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. InSilico Medicine Cayman (HKG: 03696) is based in Hong Kong, MA and was founded in 2014. It is now publicly traded; this page covers its private-market history, where its last recorded valuation was $1.7 billion (Dec 2025). It has raised $842 million across 6 recorded rounds; the latest was a $13 million Series E extension (final close) in Jun 2025.
Last price · $/share
—
Implied valuation
$1.7B
Total raised
$841.9M
Last round
Series E extension (final close)
Jun 2025
Cap table — not yet on record
InSilico Medicine Cayman (HKG: 03696)'s share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of InSilico Medicine Cayman (HKG: 03696) with a free account
·The complete investor list: 50 names
·Watch InSilico Medicine Cayman (HKG: 03696): the Monday email on marks, rounds and moves
Frequently asked about InSilico Medicine Cayman (HKG: 03696)
Where does InSilico Medicine Cayman (HKG: 03696)'s cap table come from?
Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across InSilico Medicine Cayman (HKG: 03696)'s 6 recorded funding rounds.
